Loading
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (13 ops.)
Latest filing published 10 Jul 2023 for KYNTRA BIO, INC., €4,834.
Filing timeline
BuySaleEnrique A. Conterno
Insider track record
Disclosed buys
2
Disclosed sells
13
Signal history
Closed purchases
Market purchases
2
Positive at T+90
100%
Median T+90
+7.1%
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -34.4%Entry US$984.25 · Close at T+365 US$645.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Enrique A. Conterno: trading record in brief
Enrique A. Conterno appears in 46 filings published from January 28, 2016 to July 10, 2023, for two companies: Kyntra Bio, Inc. (28, as Chief Executive Officer) and Eli Lilly & Co (18, under the title SVP&Pres, LillyDiab & LillyUSA).
Purchases exist but are rare: 2, on June 10, 2020 (EUR 255,441) and June 11, 2020 (EUR 618,833), EUR 874,274 in all, at Kyntra Bio. Against them stand 13 sales worth EUR 8,096,241, median EUR 230,975; the three largest were all at Eli Lilly: EUR 2,678,093 on February 15, 2019, EUR 1,884,073 on May 4, 2017 and EUR 1,817,300 on May 31, 2018. Purchases form 13% of market trades. The record also holds 26 share grants and 5 option exercises.
The pace rises over time, from 3 filings in 2016 to 12 in 2023. None falls in the last twelve months.
At Kyntra Bio, 10 of Conterno's trades fall within 30 days of trades by Christine Chung and as many of Thane Wettig's, always in the same direction.
Companies and markets linked to Enrique A. Conterno
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations46 total
1,880 shares@ US$2.800.4% of flowCommon StockSEC:0001209191-23-041969:0
6,106 shares@ US$17.043.2% of flowCommon StockSEC:0001209191-23-036051:1
2,791 shares@ US$17.03683.5% of flowCommon StockSEC:0001209191-23-036051:0
1,869 shares@ US$19.522.7% of flowCommon StockSEC:0001209191-23-024026:0
19,489 shares@ US$20.197329.5% of flowCommon StockSEC:0001209191-23-020781:0
12,103 shares@ US$20.207.7% of flowCommon StockSEC:0001209191-23-018064:3
19,486 shares@ US$20.2012.4% of flowCommon StockSEC:0001209191-23-018064:4
23,120 shares0Common StockSEC:0001209191-23-018064:1
37,229 shares0Common StockSEC:0001209191-23-018064:2
24,672 shares@ US$21.155939.2% of flowCommon StockSEC:0001209191-23-018064:0
85,300 shares0Common StockSEC:0001209191-23-012423:0
1,538 shares@ US$19.952.3% of flowCommon StockSEC:0001209191-23-002803:0
2,543 shares@ US$15.793.0% of flowCommon StockSEC:0001209191-22-060580:0
1,296 shares@ US$14.261.5% of flowCommon StockSEC:0001209191-22-053355:0
1,772 shares@ US$12.261.7% of flowCommon StockSEC:0001209191-22-049223:0
1,296 shares@ US$12.401.3% of flowCommon StockSEC:0001209191-22-041664:0
1,772 shares@ US$9.501.2% of flowCommon StockSEC:0001209191-22-035219:0
1,311 shares@ US$12.731.2% of flowCommon StockSEC:0001209191-22-023840:0
7,081 shares@ US$12.696.5% of flowCommon StockSEC:0001209191-22-017646:0
179,400 shares0Common StockSEC:0001209191-22-010447:0
1,536 shares@ US$13.931.5% of flowCommon StockSEC:0001209191-22-002496:0
1,859 shares@ US$10.201.3% of flowCommon StockSEC:0001209191-21-060056:0
1,859 shares@ US$25.063.1% of flowCommon StockSEC:0001209191-21-046078:0
82,000 shares0Common StockSEC:0001209191-21-015005:0
5,411 shares@ US$38.317.3% of flowCommon StockSEC:0001209191-21-002837:0
25 of 46 declarations
